67,519 Shares in Illumina, Inc. (NASDAQ:ILMN) Purchased by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 67,519 shares of the life sciences company's stock, valued at approximately $9,023,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Versant Capital Management Inc raised its position in shares of Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock valued at $32,000 after purchasing an additional 146 shares during the last quarter. Golden State Wealth Management LLC acquired a new position in Illumina during the 4th quarter valued at approximately $32,000. Assetmark Inc. raised its holdings in shares of Illumina by 954.8% in the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after buying an additional 296 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new position in shares of Illumina in the fourth quarter worth $45,000. Finally, Lee Danner & Bass Inc. acquired a new stake in shares of Illumina during the fourth quarter worth $48,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Price Performance

Shares of ILMN stock traded up $3.52 on Friday, reaching $74.78. 3,040,860 shares of the company were exchanged, compared to its average volume of 2,265,473. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The business has a 50-day moving average price of $88.58 and a 200 day moving average price of $122.32. The company has a market cap of $11.85 billion, a price-to-earnings ratio of -9.74, a P/E/G ratio of 1.60 and a beta of 1.38.

Remove Ads

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Equities research analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on ILMN shares. Morgan Stanley reduced their target price on Illumina from $150.00 to $136.00 and set an "equal weight" rating for the company in a research note on Tuesday, February 11th. Royal Bank of Canada reduced their price objective on Illumina from $128.00 to $112.00 and set an "outperform" rating for the company in a research note on Tuesday. Guggenheim dropped their target price on Illumina from $170.00 to $150.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. Piper Sandler raised their price target on shares of Illumina from $185.00 to $190.00 and gave the stock an "overweight" rating in a research report on Monday, February 10th. Finally, Barclays decreased their price objective on shares of Illumina from $100.00 to $77.00 and set an "underweight" rating for the company in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $138.70.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.